aluates Reports

$ 0.0

Automative

COVID-19 Recombinant Protein Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: December 2024

Report Code: QYRE-Auto-6P6138

Global COVID 19 Recombinant Protein Vaccine Market Size Status and Forecast 2022 2028

BUY CHAPTERS

COVID-19 Recombinant Protein Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-6P6138

Report

December 2024

Pages:83

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

GSK

Johnson & Johnson

Sanofi

Novavax Inc

Pukang Biologic Technology

Clover Biopharmaceuticals

Suzhou Yuzhibo Biotechnology

COVID-19 Recombinant Protein Vaccine - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

COVID-19 Recombinant Protein Vaccine - Market

Preparation and immunogenicity and immunoprotection of Hib polysaccharide conjugate vaccine based on pneumococcal surface adhesive (PsaA).Methods PsaA gene recombinant protein (rPsaA) was prepared by genetic engineering, and then conjugated with Hib polysaccharide by amide condensation.The 3-week-old mice were immunized with this vaccine, and mice were inoculated with tetanus toxoid and haemophilus influenzae type B (Hib) polysaccharide conjugate vaccine (hib-tt) as controls and phosphate buffer (PBS) as blank controls.

The global market for COVID-19 Recombinant Protein Vaccine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for COVID-19 Recombinant Protein Vaccine, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of COVID-19 Recombinant Protein Vaccine by region & country, by Type, and by Application.

The COVID-19 Recombinant Protein Vaccine market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding COVID-19 Recombinant Protein Vaccine.

Market Segmentation

Scope of COVID-19 Recombinant Protein Vaccine - Market Report

Report Metric	Details
Report Name	COVID-19 Recombinant Protein Vaccine - Market
CAGR	5%
Segment by Type:	Being Developed Preclinical Clinical I Clinical II
Segment by Application	Pharmaceutical And Biotechnology Companies Hospital Academic And Research Organizations Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	GSK, Johnson & Johnson, Sanofi, Novavax, Pukang Biologic Technology, Clover Biopharmaceuticals, Suzhou Yuzhibo Biotechnology
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of COVID-19 Recombinant Protein Vaccine manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of COVID-19 Recombinant Protein Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of COVID-19 Recombinant Protein Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the COVID-19 Recombinant Protein Vaccine - Market report?

Ans: The main players in the COVID-19 Recombinant Protein Vaccine - Market are GSK, Johnson & Johnson, Sanofi, Novavax, Pukang Biologic Technology, Clover Biopharmaceuticals, Suzhou Yuzhibo Biotechnology

What are the Application segmentation covered in the COVID-19 Recombinant Protein Vaccine - Market report?

Ans: The Applications covered in the COVID-19 Recombinant Protein Vaccine - Market report are Pharmaceutical And Biotechnology Companies, Hospital, Academic And Research Organizations, Other

What are the Type segmentation covered in the COVID-19 Recombinant Protein Vaccine - Market report?

Ans: The Types covered in the COVID-19 Recombinant Protein Vaccine - Market report are Being Developed, Preclinical, Clinical I, Clinical II

Recommended Reports

COVID-19 Vaccines

Protein and Recombinant Vaccines

Broader Vaccine Market

1 Market Overview

1.1 COVID-19 Recombinant Protein Vaccine Product Introduction

1.2 Global COVID-19 Recombinant Protein Vaccine Market Size Forecast

1.3 COVID-19 Recombinant Protein Vaccine Market Trends & Drivers

1.3.1 COVID-19 Recombinant Protein Vaccine Industry Trends

1.3.2 COVID-19 Recombinant Protein Vaccine Market Drivers & Opportunity

1.3.3 COVID-19 Recombinant Protein Vaccine Market Challenges

1.3.4 COVID-19 Recombinant Protein Vaccine Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global COVID-19 Recombinant Protein Vaccine Players Revenue Ranking (2023)

2.2 Global COVID-19 Recombinant Protein Vaccine Revenue by Company (2019-2024)

2.3 Key Companies COVID-19 Recombinant Protein Vaccine Manufacturing Base Distribution and Headquarters

2.4 Key Companies COVID-19 Recombinant Protein Vaccine Product Offered

2.5 Key Companies Time to Begin Mass Production of COVID-19 Recombinant Protein Vaccine

2.6 COVID-19 Recombinant Protein Vaccine Market Competitive Analysis

2.6.1 COVID-19 Recombinant Protein Vaccine Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by COVID-19 Recombinant Protein Vaccine Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Recombinant Protein Vaccine as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Being Developed

3.1.2 Preclinical

3.1.3 Clinical I

3.1.4 Clinical II

3.2 Global COVID-19 Recombinant Protein Vaccine Sales Value by Type

3.2.1 Global COVID-19 Recombinant Protein Vaccine Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global COVID-19 Recombinant Protein Vaccine Sales Value, by Type (2019-2030)

3.2.3 Global COVID-19 Recombinant Protein Vaccine Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Pharmaceutical And Biotechnology Companies

4.1.2 Hospital

4.1.3 Academic And Research Organizations

4.1.4 Other

4.2 Global COVID-19 Recombinant Protein Vaccine Sales Value by Application

4.2.1 Global COVID-19 Recombinant Protein Vaccine Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global COVID-19 Recombinant Protein Vaccine Sales Value, by Application (2019-2030)

4.2.3 Global COVID-19 Recombinant Protein Vaccine Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global COVID-19 Recombinant Protein Vaccine Sales Value by Region

5.1.1 Global COVID-19 Recombinant Protein Vaccine Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global COVID-19 Recombinant Protein Vaccine Sales Value by Region (2019-2024)

5.1.3 Global COVID-19 Recombinant Protein Vaccine Sales Value by Region (2025-2030)

5.1.4 Global COVID-19 Recombinant Protein Vaccine Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America COVID-19 Recombinant Protein Vaccine Sales Value, 2019-2030

5.2.2 North America COVID-19 Recombinant Protein Vaccine Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe COVID-19 Recombinant Protein Vaccine Sales Value, 2019-2030

5.3.2 Europe COVID-19 Recombinant Protein Vaccine Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific COVID-19 Recombinant Protein Vaccine Sales Value, 2019-2030

5.4.2 Asia Pacific COVID-19 Recombinant Protein Vaccine Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America COVID-19 Recombinant Protein Vaccine Sales Value, 2019-2030

5.5.2 South America COVID-19 Recombinant Protein Vaccine Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa COVID-19 Recombinant Protein Vaccine Sales Value, 2019-2030

5.6.2 Middle East & Africa COVID-19 Recombinant Protein Vaccine Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions COVID-19 Recombinant Protein Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions COVID-19 Recombinant Protein Vaccine Sales Value

6.3 United States

6.3.1 United States COVID-19 Recombinant Protein Vaccine Sales Value, 2019-2030

6.3.2 United States COVID-19 Recombinant Protein Vaccine Sales Value by Type (%), 2023 VS 2030

6.3.3 United States COVID-19 Recombinant Protein Vaccine Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe COVID-19 Recombinant Protein Vaccine Sales Value, 2019-2030

6.4.2 Europe COVID-19 Recombinant Protein Vaccine Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe COVID-19 Recombinant Protein Vaccine Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China COVID-19 Recombinant Protein Vaccine Sales Value, 2019-2030

6.5.2 China COVID-19 Recombinant Protein Vaccine Sales Value by Type (%), 2023 VS 2030

6.5.3 China COVID-19 Recombinant Protein Vaccine Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan COVID-19 Recombinant Protein Vaccine Sales Value, 2019-2030

6.6.2 Japan COVID-19 Recombinant Protein Vaccine Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan COVID-19 Recombinant Protein Vaccine Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea COVID-19 Recombinant Protein Vaccine Sales Value, 2019-2030

6.7.2 South Korea COVID-19 Recombinant Protein Vaccine Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea COVID-19 Recombinant Protein Vaccine Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia COVID-19 Recombinant Protein Vaccine Sales Value, 2019-2030

6.8.2 Southeast Asia COVID-19 Recombinant Protein Vaccine Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia COVID-19 Recombinant Protein Vaccine Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India COVID-19 Recombinant Protein Vaccine Sales Value, 2019-2030

6.9.2 India COVID-19 Recombinant Protein Vaccine Sales Value by Type (%), 2023 VS 2030

6.9.3 India COVID-19 Recombinant Protein Vaccine Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 GSK

7.1.1 GSK Profile

7.1.2 GSK Main Business

7.1.3 GSK COVID-19 Recombinant Protein Vaccine Products, Services and Solutions

7.1.4 GSK COVID-19 Recombinant Protein Vaccine Revenue (US$ Million) & (2019-2024)

7.1.5 GSK Recent Developments

7.2 Johnson & Johnson

7.2.1 Johnson & Johnson Profile

7.2.2 Johnson & Johnson Main Business

7.2.3 Johnson & Johnson COVID-19 Recombinant Protein Vaccine Products, Services and Solutions

7.2.4 Johnson & Johnson COVID-19 Recombinant Protein Vaccine Revenue (US$ Million) & (2019-2024)

7.2.5 Johnson & Johnson Recent Developments

7.3 Sanofi

7.3.1 Sanofi Profile

7.3.2 Sanofi Main Business

7.3.3 Sanofi COVID-19 Recombinant Protein Vaccine Products, Services and Solutions

7.3.4 Sanofi COVID-19 Recombinant Protein Vaccine Revenue (US$ Million) & (2019-2024)

7.3.5 Novavax Recent Developments

7.4 Novavax

7.4.1 Novavax Profile

7.4.2 Novavax Main Business

7.4.3 Novavax COVID-19 Recombinant Protein Vaccine Products, Services and Solutions

7.4.4 Novavax COVID-19 Recombinant Protein Vaccine Revenue (US$ Million) & (2019-2024)

7.4.5 Novavax Recent Developments

7.5 Pukang Biologic Technology

7.5.1 Pukang Biologic Technology Profile

7.5.2 Pukang Biologic Technology Main Business

7.5.3 Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Products, Services and Solutions

7.5.4 Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Revenue (US$ Million) & (2019-2024)

7.5.5 Pukang Biologic Technology Recent Developments

7.6 Clover Biopharmaceuticals

7.6.1 Clover Biopharmaceuticals Profile

7.6.2 Clover Biopharmaceuticals Main Business

7.6.3 Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Products, Services and Solutions

7.6.4 Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Revenue (US$ Million) & (2019-2024)

7.6.5 Clover Biopharmaceuticals Recent Developments

7.7 Suzhou Yuzhibo Biotechnology

7.7.1 Suzhou Yuzhibo Biotechnology Profile

7.7.2 Suzhou Yuzhibo Biotechnology Main Business

7.7.3 Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Products, Services and Solutions

7.7.4 Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Revenue (US$ Million) & (2019-2024)

7.7.5 Suzhou Yuzhibo Biotechnology Recent Developments

8 Industry Chain Analysis

8.1 COVID-19 Recombinant Protein Vaccine Industrial Chain

8.2 COVID-19 Recombinant Protein Vaccine Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 COVID-19 Recombinant Protein Vaccine Sales Model

8.5.2 Sales Channel

8.5.3 COVID-19 Recombinant Protein Vaccine Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

GSK

Johnson & Johnson

Sanofi

Novavax Inc

Pukang Biologic Technology

Clover Biopharmaceuticals

Suzhou Yuzhibo Biotechnology

List of Tables

Table 1. COVID-19 Recombinant Protein Vaccine Market Trends

Table 2. COVID-19 Recombinant Protein Vaccine Market Drivers & Opportunity

Table 3. COVID-19 Recombinant Protein Vaccine Market Challenges

Table 4. COVID-19 Recombinant Protein Vaccine Market Restraints

Table 5. Global COVID-19 Recombinant Protein Vaccine Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global COVID-19 Recombinant Protein Vaccine Revenue Market Share by Company (2019-2024)

Table 7. Key Companies COVID-19 Recombinant Protein Vaccine Manufacturing Base Distribution and Headquarters

Table 8. Key Companies COVID-19 Recombinant Protein Vaccine Product Type

Table 9. Key Companies Time to Begin Mass Production of COVID-19 Recombinant Protein Vaccine

Table 10. Global COVID-19 Recombinant Protein Vaccine Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Recombinant Protein Vaccine as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global COVID-19 Recombinant Protein Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global COVID-19 Recombinant Protein Vaccine Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global COVID-19 Recombinant Protein Vaccine Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global COVID-19 Recombinant Protein Vaccine Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global COVID-19 Recombinant Protein Vaccine Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global COVID-19 Recombinant Protein Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global COVID-19 Recombinant Protein Vaccine Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global COVID-19 Recombinant Protein Vaccine Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global COVID-19 Recombinant Protein Vaccine Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global COVID-19 Recombinant Protein Vaccine Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global COVID-19 Recombinant Protein Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global COVID-19 Recombinant Protein Vaccine Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global COVID-19 Recombinant Protein Vaccine Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global COVID-19 Recombinant Protein Vaccine Sales Value by Region (2019-2024) & (%)

Table 27. Global COVID-19 Recombinant Protein Vaccine Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions COVID-19 Recombinant Protein Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions COVID-19 Recombinant Protein Vaccine Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions COVID-19 Recombinant Protein Vaccine Sales Value, (2025-2030) & (US$ Million)

Table 31. GSK Basic Information List

Table 32. GSK Description and Business Overview

Table 33. GSK COVID-19 Recombinant Protein Vaccine Products, Services and Solutions

Table 34. Revenue (US$ Million) in COVID-19 Recombinant Protein Vaccine Business of GSK (2019-2024)

Table 35. GSK Recent Developments

Table 36. Johnson & Johnson Basic Information List

Table 37. Johnson & Johnson Description and Business Overview

Table 38. Johnson & Johnson COVID-19 Recombinant Protein Vaccine Products, Services and Solutions

Table 39. Revenue (US$ Million) in COVID-19 Recombinant Protein Vaccine Business of Johnson & Johnson (2019-2024)

Table 40. Johnson & Johnson Recent Developments

Table 41. Sanofi Basic Information List

Table 42. Sanofi Description and Business Overview

Table 43. Sanofi COVID-19 Recombinant Protein Vaccine Products, Services and Solutions

Table 44. Revenue (US$ Million) in COVID-19 Recombinant Protein Vaccine Business of Sanofi (2019-2024)

Table 45. Sanofi Recent Developments

Table 46. Novavax Basic Information List

Table 47. Novavax Description and Business Overview

Table 48. Novavax COVID-19 Recombinant Protein Vaccine Products, Services and Solutions

Table 49. Revenue (US$ Million) in COVID-19 Recombinant Protein Vaccine Business of Novavax (2019-2024)

Table 50. Novavax Recent Developments

Table 51. Pukang Biologic Technology Basic Information List

Table 52. Pukang Biologic Technology Description and Business Overview

Table 53. Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Products, Services and Solutions

Table 54. Revenue (US$ Million) in COVID-19 Recombinant Protein Vaccine Business of Pukang Biologic Technology (2019-2024)

Table 55. Pukang Biologic Technology Recent Developments

Table 56. Clover Biopharmaceuticals Basic Information List

Table 57. Clover Biopharmaceuticals Description and Business Overview

Table 58. Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Products, Services and Solutions

Table 59. Revenue (US$ Million) in COVID-19 Recombinant Protein Vaccine Business of Clover Biopharmaceuticals (2019-2024)

Table 60. Clover Biopharmaceuticals Recent Developments

Table 61. Suzhou Yuzhibo Biotechnology Basic Information List

Table 62. Suzhou Yuzhibo Biotechnology Description and Business Overview

Table 63. Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Products, Services and Solutions

Table 64. Revenue (US$ Million) in COVID-19 Recombinant Protein Vaccine Business of Suzhou Yuzhibo Biotechnology (2019-2024)

Table 65. Suzhou Yuzhibo Biotechnology Recent Developments

Table 66. Key Raw Materials Lists

Table 67. Raw Materials Key Suppliers Lists

Table 68. COVID-19 Recombinant Protein Vaccine Downstream Customers

Table 69. COVID-19 Recombinant Protein Vaccine Distributors List

Table 70. Research Programs/Design for This Report

Table 71. Key Data Information from Secondary Sources

Table 72. Key Data Information from Primary Sources

Table 73. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. COVID-19 Recombinant Protein Vaccine Product Picture

Figure 2. Global COVID-19 Recombinant Protein Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global COVID-19 Recombinant Protein Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 4. COVID-19 Recombinant Protein Vaccine Report Years Considered

Figure 5. Global COVID-19 Recombinant Protein Vaccine Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by COVID-19 Recombinant Protein Vaccine Revenue in 2023

Figure 7. COVID-19 Recombinant Protein Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Being Developed Picture

Figure 9. Preclinical Picture

Figure 10. Clinical I Picture

Figure 11. Clinical II Picture

Figure 12. Global COVID-19 Recombinant Protein Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 13. Global COVID-19 Recombinant Protein Vaccine Sales Value Market Share by Type, 2023 & 2030

Figure 14. Product Picture of Pharmaceutical And Biotechnology Companies

Figure 15. Product Picture of Hospital

Figure 16. Product Picture of Academic And Research Organizations

Figure 17. Product Picture of Other

Figure 18. Global COVID-19 Recombinant Protein Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 19. Global COVID-19 Recombinant Protein Vaccine Sales Value Market Share by Application, 2023 & 2030

Figure 20. North America COVID-19 Recombinant Protein Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 21. North America COVID-19 Recombinant Protein Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 22. Europe COVID-19 Recombinant Protein Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 23. Europe COVID-19 Recombinant Protein Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 24. Asia Pacific COVID-19 Recombinant Protein Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 25. Asia Pacific COVID-19 Recombinant Protein Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 26. South America COVID-19 Recombinant Protein Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 27. South America COVID-19 Recombinant Protein Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 28. Middle East & Africa COVID-19 Recombinant Protein Vaccine Sales Value (2019-2030) & (US$ Million)

Figure 29. Middle East & Africa COVID-19 Recombinant Protein Vaccine Sales Value by Country (%), 2023 VS 2030

Figure 30. Key Countries/Regions COVID-19 Recombinant Protein Vaccine Sales Value (%), (2019-2030)

Figure 31. United States COVID-19 Recombinant Protein Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 32. United States COVID-19 Recombinant Protein Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 33. United States COVID-19 Recombinant Protein Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 34. Europe COVID-19 Recombinant Protein Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 35. Europe COVID-19 Recombinant Protein Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 36. Europe COVID-19 Recombinant Protein Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 37. China COVID-19 Recombinant Protein Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 38. China COVID-19 Recombinant Protein Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 39. China COVID-19 Recombinant Protein Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 40. Japan COVID-19 Recombinant Protein Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 41. Japan COVID-19 Recombinant Protein Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 42. Japan COVID-19 Recombinant Protein Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 43. South Korea COVID-19 Recombinant Protein Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 44. South Korea COVID-19 Recombinant Protein Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 45. South Korea COVID-19 Recombinant Protein Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 46. Southeast Asia COVID-19 Recombinant Protein Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 47. Southeast Asia COVID-19 Recombinant Protein Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 48. Southeast Asia COVID-19 Recombinant Protein Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 49. India COVID-19 Recombinant Protein Vaccine Sales Value, (2019-2030) & (US$ Million)

Figure 50. India COVID-19 Recombinant Protein Vaccine Sales Value by Type (%), 2023 VS 2030

Figure 51. India COVID-19 Recombinant Protein Vaccine Sales Value by Application (%), 2023 VS 2030

Figure 52. COVID-19 Recombinant Protein Vaccine Industrial Chain

Figure 53. COVID-19 Recombinant Protein Vaccine Manufacturing Cost Structure

Figure 54. Channels of Distribution (Direct Sales, and Distribution)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

COVID 19 DNA Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

COVID 19 Inactivated Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

COVID 19 RNA Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Covid 19 Vaccine Bottle Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Approved COVID 19 Vaccines Market Research Report 2025

Oral COVID 19 Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

COVID 19 Vaccine Transportation Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

COVID 19 Vaccines Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

13 Valent Pneumococcal Polysaccharide Conjugate Vaccine PCV13 Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Pneumococcal Conjugate Vaccine PCV Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Covid 19 Vaccine Logistics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Novel Coronavirus COVID 19 Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

COVID 19 Vaccine Cold Chain Logistics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

23 valent Pneumococcal Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Vials for COVID 19 Vaccine Market Research Report 2024

Streptococcus Pneumoniae Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Recombinant Protein Vaccine Market Insights Forecast to 2030

Recombinant Glycosylated Proteins Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Recombinant Novel Coronavirus Vaccine for Inhalation Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions